-
more
R & D
Ono Pharma Receives Orphan Medicinal Product Designation for Sapablursen from European Commission and Plans to Present Trial-in-Progress Poster at ASH 2026
-
more
R & D
Ono Pharma Announces Results from Five Phase 2 Clinical Studies of ONO-1110, an Endocannabinoid Modulator
-
more
Management / Finance
Announcement on Financial Results for FY2026 Q2
-
more
Licensing
Ono Pharma Announces an Exclusive License Agreement with Biohaven to Develop and Commercialize IgG Degraders in Japan, South Korea, Taiwan, and ASEAN Countries
-
more
Corporate
Ono Venture Investment Relocates to Cambridge, Massachusetts
— Accelerating Open Innovation and Maximizing Strategic Returns —
Performance Reports
Financial Highlights
Financial Strategy
